Frost has fully develop drug discovery capabilities and specializes in developing new experimental therapeutics with minimal resources. Founded upon a licensed phenotypic screening technology to identify compounds that could be optimized as small molecule cancer drugs, Frost Biologic has a decade-long track record of successfully reaching drug discovery milestones with minimal resources. The legacy of this work is FROST450, a clinical candidate being prepared for clinical trials in oncology.
The most successful anticancer drugs in history target the microtubule cytoskeleton, but they face limitations arising from drug resistance and lack of oral bioavailability. Frost Biologic is preparing to launch phase I clinical trials of FROST450, a novel microtubule targeting drug that has pharmacology that could dramatically alter cancer treatment. FROST450 overcomes drug resistance to other microtubule targeting drugs, evades multidrug resistance machines, and is orally available with gastric absorption.